dc.contributor
Institut Català de la Salut
dc.contributor
[Kramer CJ, Ter Haar NT] Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. [Llop-Guevara A, Herencia-Ropero A, Serra V] Grup de Terapèutica Experimental, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. [Yaniz-Galende E] Department of Oncology, Institute Gustave Roussy, Villejuif, France. [Pellegrino B] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Kramer, Claire
dc.contributor.author
Yaniz-Galende, Elisa
dc.contributor.author
Pellegrino, Benedetta
dc.contributor.author
ter Haar, Natalja
dc.contributor.author
Llop-Guevara, Alba
dc.contributor.author
Herencia Ropero, Andrea
dc.contributor.author
Serra, Violeta
dc.date.accessioned
2025-10-25T05:38:37Z
dc.date.available
2025-10-25T05:38:37Z
dc.date.issued
2023-10-16T08:32:16Z
dc.date.issued
2023-10-16T08:32:16Z
dc.identifier
Kramer CJH, Llop-Guevara A, Yaniz-Galende E, Pellegrino B, ter Haar NT, Herencia-Ropero A, et al. RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test. J Pathol Clin Res. 2023 Nov;9(6):442–8.
dc.identifier
https://hdl.handle.net/11351/10446
dc.identifier
10.1002/cjp2.336
dc.identifier
001037713300001
dc.identifier.uri
http://hdl.handle.net/11351/10446
dc.description.abstract
Biomarker; High-hrade serous ovarian carcinoma; Homologous recombination deficiency
dc.description.abstract
Biomarcador; Carcinoma de ovario seroso de alto grado; Deficiencia de recombinación homóloga
dc.description.abstract
Biomarcador; Carcinoma d'ovari serós d'alt grau; Deficiència de recombinació homòloga
dc.description.abstract
The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence-based RAD51 test, in different academic laboratories, have not been systematically investigated. Therefore, we tested the performance of the RAD51 assay in formalin-fixed paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples in four European laboratories. Here, we confirm that subtle differences in staining procedures result in low variability of RAD51 and γH2AX scores. However, substantial variability in RAD51 scoring was observed in some samples, likely due to complicating technical and biological features, such as high RAD51 signal-to-noise ratio and RAD51 heterogeneity. These results support the need to identify and perform additional quality control steps and/or automating image analysis. Altogether, resolving technical issues should be a priority, as identifying tumours with functional HRD is urgently needed to guide the individual treatment of HGSOC patients. Follow-up studies are needed to define the key tissue quality requirements to assess HRD by RAD51 in FFPE tumour samples, as this test could help in guiding the individual treatment of HGSOC patients.
dc.description.abstract
This work was supported by the Dutch Cancer Society (KWF) (grant: 12995 to TB and MV) and by ERA PerMed (grant ERAPERMED2019-215 to VS). VS received funding from Instituto de Salud Carlos III (CPII19/00033). ALG received funding from Asociación Española Contra el Cáncer (AECC) (INVES20095LLOP) and AHR from Generalitat de Catalunya (PERIS SLT017/20/000081).
dc.format
application/pdf
dc.format
application/pdf
dc.relation
The Journal of Pathology: Clinical Research;9(6)
dc.relation
https://doi.org/10.1002/cjp2.336
dc.relation
info:eu-repo/grantAgreement/ES/PE2017-2020/CPII19%2F00033
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Ovaris - Càncer - Aspectes genètics
dc.subject
Marcadors tumorals
dc.subject
Recombinació genètica
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::Recombination, Genetic::Homologous Recombination
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
dc.subject
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Recombinases::Rec A Recombinases::Rad51 Recombinase
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::recombinación genética::recombinación homóloga
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::recombinasas::rec a recombinasas::rad51 recombinasa
dc.title
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion